| Document |
Document Title |
|
WO/1999/062870A1 |
A novel compound 3-{4-[2-(4-$i(tert)-Butoxycarbonylaminophenyl)ethoxy]phenyl}
-(S)-2-ethoxy propanoic acid having formula (I) and pharmaceutically acceptable salts, solvates, and crystalline forms thereof, a process and intermediates for...
|
|
WO/1999/062872A1 |
A novel 3-aryl-2-hydroxypropionic acid derivative, having formula (I) and pharmaceutically acceptable salts, solvates, and crystalline forms thereof, a process and intermediate for its manufacture, pharmaceutical preparations containing ...
|
|
WO/1999/062869A1 |
Phenylacetylene derivatives represented by general formula (I) and agricultural/horticultural bactericides containing the same as the active ingredient, wherein X represents halogeno, C¿1-6? alkyl, C¿2-6? alkoxy, C¿2-6? haloalkyl, etc...
|
|
WO/1999/062871A1 |
Novel 3-aryl proprionic acid derivatives and analogs, having general formula (I) and stereo- and optical isomers and racemates thereof as well as pharmaceutically acceptable salts, solvates and crystalline forms thereof, process for thei...
|
|
WO/1999/062867A1 |
Cardiac failure remedies containing as the active ingredient indan derivatives represented by general formula (I) or medicinally acceptable salts thereof, wherein R?1¿ is hydrogen, nitro, cyano, amino, C¿1?-C¿6? alkylcarbonylamino or ...
|
|
WO/1999/061410A1 |
This invention provides compounds of Formula (I) having structure (I) wherein: B and D are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, heteroaryl, aralkyl of 6-12 carbon atoms,...
|
|
WO/1999/058495A1 |
The invention concerns compounds of formula (I): R-A-R' wherein: A is as defined in the description; R represents a group (V), wherein R'¿a? and R''¿a? are as defined in the description, or R forms with A a cyclic structure as defined ...
|
|
WO/1999/058496A1 |
The invention concerns compounds of formula (I): R-A-R' wherein: A is as defined in the description; R represents a group (V), (VI), (VII) or (VIII), where E, Q, R?1¿, R?2¿, R?3¿, v and R?4¿ are as defined in the description; R' repr...
|
|
WO/1999/058502A1 |
The present invention relates to inhibitors of p38, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The in...
|
|
WO/1999/054279A1 |
This invention relates to a series of substituted amino acids of formula (I), pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the e...
|
|
WO/1999/054321A1 |
The invention is directed to physiologically active compounds of general formula (I): wherein R?1¿ represents R?5¿-L?3¿-, R?5¿-L?4¿-R?6¿-, R?5¿-L?4¿-R?7¿-L?5¿-, R?5¿-L?4¿-Ar?1¿-L?3¿-, R?5¿-L?4¿-Ar?1¿-L?6¿-R?6¿- or R?5Â...
|
|
WO/1999/052879A1 |
Compounds of formula (I) are useful in the treatment of various disorders including, but not limited to, cancer, angiogenesis, restenosis, inflammation, bone diseases, and as antiviral agents. Novel methods of makings compounds of formul...
|
|
WO/1999/051564A1 |
This invention relates to new propanolamine derivatives or salts thereof represented by general formula (I), wherein each symbol is as defined in the specification or salts thereof which are $g(b)¿3? adrergenic receptor agonists and the...
|
|
WO/1999/051570A1 |
Disclosed is an anion-complexing compound (I) wherein R1 and A represent an aromatic 6-ring, Y' represents a -NHC(X)NH-group, and Y' represents a rest selected from the group -NHC(X')-, -C(X')NH- and -NHC(X')NH-, wherein X and X', indepe...
|
|
WO/1999/047494A1 |
The invention concerns compounds corresponding to general formula (I) and their salts, hydrates and solvates physiologically acceptable for therapeutic use. The invention also concerns a method for preparing said compounds, their applica...
|
|
WO/1999/044425A1 |
The present invention provides pharmaceutical or veterinary compositions comprising, a carrier and an active ingredient being a compound of formula (I), wherein R?1¿ and R?2¿ are each independently hydrogen, halogen or methoxy, as well...
|
|
WO/1999/041218A1 |
The present invention relates to a method of making alpha-methylstyrene dimers by combining a cobalt catalyst, a free-radical initiator and an alpha-methylstyrene monomer, in an inert atmosphere, to form a mixture. The mixture is heated ...
|
|
WO/1999/038846A1 |
Disclosed are methods of suppressing the immune system in a subject in need of immune system suppression. The method comprises administering to the subject an effective amount of a compound represented by Structural Formulas (I, II, III ...
|
|
WO/1999/037605A1 |
Compounds of formula (I) and their pharmaceutically acceptable salts are VLA-4 antagonists. They are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of inflammatory and autoimmune diseases, particularl...
|
|
WO/1999/037604A2 |
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in...
|
|
WO/1999/036393A1 |
The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, -O...
|
|
WO/1999/036455A1 |
The invention relates to diisocyanates of formula (I) in which the radicals have the following meanings: R?1¿, R?2¿: both radicals are a radical of formula (II) -CH¿2?-CH¿2?-CH¿2?-CH¿2?-CH¿2?-CH¿2?- (diisocyanates Ia); one radica...
|
|
WO/1999/036392A1 |
The invention concerns compounds of formula (I) in which: A forms a tricyclic system of formula A¿1?, A¿2?, A¿3? or A¿4?; R?1¿ represents a hydrogen atom, an alkyl, hydroxy, alkoxy or oxo group; (R?2¿)¿m? and (R?3¿)¿m'? are such...
|
|
WO/1999/033789A1 |
The invention is directed to physiologically active compounds of general formula (I), wherein R?1¿ is hydrogen, halogen, lower alkyl or lower alkoxy; X?1¿, X?2¿ and X?6¿ independently represent N or CR?2¿; and one of X?3¿, X?4¿ an...
|
|
WO/1999/033790A1 |
Fluoro-substituted benzoylureas of formula (I) wherein R?1¿, R?2¿ and R?3¿ each independently represent a hydrogen atom, nitro, cyano, halogen, C¿1-3?-alkyl, C¿1-3?-haloalkyl, C¿1-3?-alkoxy, C¿1-3?-haloalkoxy, C¿1-3?-alkylthio or...
|
|
WO/1999/032437A1 |
The invention relates to 1,3-disubstituted ureas of general formula (I) where R?1¿ is an aryl, R?2¿ is nitro and/or amino, and X is oxygen and/or sulfur, and the method of preparing thereof which consists in treating aromatic amines wi...
|
|
WO/1999/032106A1 |
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
|
|
WO/1999/032436A1 |
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
|
|
WO/1999/032463A1 |
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
|
|
WO/1999/032433A1 |
The present invention provides compounds of formula (I). The present invention also provides methods of treating or preventing inflammation or atherosclerosis, and a pharmaceutical composition that contains a compound of formula (I).
|
|
WO/1999/031049A1 |
Compounds of formula (I) wherein: Q represents an amidino group, a cyano group or a group of formula XYN-, (where X and Y are hydrogen or various groups); R?a¿ represents alkylene; R?b¿ and R?c¿ each represents alkylene, the total num...
|
|
WO/1999/031053A1 |
An improved process for the synthesis of urea from ammonia and carbon dioxide by the use of a vertically or horizontally placed condenser, enabling the corrosion prevention of the areas in which the tube plate of the condenser is joined ...
|
|
WO/1999/029655A1 |
The invention relates to compounds of formula (I), wherein R?1¿ and R?2¿, independently from each other, mean hydrogen, halogen or C¿1-4? alkyl group; R?3¿, R?4¿ and R?5¿, independently from each other, stand for hydrogen or C¿1-4...
|
|
WO/1999/028291A1 |
Bishydroxyureas are provided that inhibit the enzyme 5-lipoxygenase. These compounds have formula (I) wherein R¿1?, R¿2?, R¿3?, R¿4?, A and M are defined herein. Also disclosed are pharmaceutical compositions containing such compound...
|
|
WO/1999/026584A2 |
Oleamide is an endogenous fatty acid primary amide that possesses sleep-inducing properties in animals and has been shown to effect seratonergic systems and block gap junction communication in a structurally specific manner. Certain agen...
|
|
WO/1999/026923A1 |
Para-aminomethylaryl carboxamides of Formula (I) are antagonists of VLA-4 and/or $g(a)¿4?$g(b)¿7?, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be f...
|
|
WO1999010312B1 |
Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compou...
|
|
WO/1999/025698A1 |
The invention relates to a method for producing ar(alk)yluraciles of general formula (I), wherein A represents a single bond or an alkanediyl, Ar represents optionally substituted aryl, R?1¿ represents optionally substituted alkyl, and ...
|
|
WO/1999/024398A2 |
Compounds of formula (II) where R?1¿ is in the para or meta position and is (A); R?2¿ and R?3¿ are each independently selected from hydrogen, nitro, C¿1-6?alkyl, C¿3-6?cycloalkyl, C¿2-6?alkenyl, C¿2-6?alkynyl, C¿1-4?alkoxyl, C¿1...
|
|
WO/1999/024403A1 |
The invention relates to the use of an N,N'-substituted carbamide from the group of substances of formula (1), wherein A represents an alkanediyl group, preferably the methylene group, O, S, SO, SO¿2? and NH; X represents alkyl, cycloal...
|
|
WO/1999/023063A1 |
The invention is directed to physiologically active compounds of formula (I) wherein: R?1¿ is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; X?1¿, X?2¿ and X?6¿ independently represent N or CR?10¿; and one of X?3¿, X?4¿ ...
|
|
WO/1999/021828A1 |
The present invention provides a simple, 1-step process for preparing a N-(aryl or heteroaryl)-hydroxyurea comprising reacting the corresponding alcohol, ester or ether with hydroxyurea and acid. This reaction is particularly useful for ...
|
|
WO/1999/019291A1 |
Compounds represented by general formula (I) or salts thereof, wherein n is an integer of 2 or 3; R represents a straight-chain or branched saturated alkyl group having 4 or 5 carbon atoms, a cyclopentyl group, a cyclohexyl group or the ...
|
|
WO/1999/018084A1 |
A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure (I) with an alkylating agent of structure (III) in the presence of a basic catalyst in an aprotic reaction medium. The ureide may ...
|
|
WO/1999/015493A1 |
The invention relates to tetracyclo[6.6.2.0?2,7¿.0?9,14¿]hexadeca-2(7),3,5,9(14),10
,12-hexaene derivatives of general formula (I), wherein R1 and R2 are hydrogen or a halogen atom and are the same or different, X is hydrogen and Y is ...
|
|
WO/1999/014253A1 |
The invention relates to novel crosslinkable prepolymers of formula (1), wherein the variables have the meanings given in the claims, to homo- or co-polymers obtainable therefrom by crosslinking and to mouldings, such as, especially, con...
|
|
WO/1999/011606A2 |
The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) and (II) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Melli...
|
|
WO/1999/010313A1 |
Compounds of formula (I) are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and /or damage are related to the binding of VC...
|
|
WO/1999/010318A1 |
The invention concerns novel aminophenol derivatives, a composition containing them and their use in a composition as depigmenting and/or bleaching agent for human skin, hairs and/or hair. The invention also concerns a method for depigme...
|
|
WO/1999/010317A1 |
Biarylalkylenecarbamic acid derivatives represented by general formula [I] and bacteriocides for agricultural and horticultural use, wherein Q is optionally substituted phenyl or the like; X is halogeno, C¿1?-C¿6? alkyl or the like; n ...
|
